HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies-Reference-Cited by-同舟云学术

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Published:2020-04-24 Issue:5 Volume:12 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Gandullo‐Sánchez Lucía¹,Capone Emily²,Ocaña Alberto³,Iacobelli Stefano⁴,Sala Gianluca²⁴^ORCID,Pandiella Atanasio¹^ORCID

Affiliation:

1. Instituto de Biología Molecular y Celular del Cáncer CSIC, IBSAL and CIBERONC Salamanca Spain

2. Department of Medical, Oral and Biotechnological Sciences Center for Advanced Studiesand Technology (CAST) University of Chieti‐Pescara Chieti Italy

3. Hospital Clínico San Carlos Madrid Spain

4. MediaPharma s.r.l Chieti Italy

Funder

Ministerio de Economía y Competitividad

Instituto de Salud Carlos III

Fundación Científica Asociación Española Contra el Cáncer

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201911498

Reference63 articles.

1. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

2. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

3. Treatment of HER2-positive breast cancer: current status and future perspectives

4. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

5. Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate;Journal of Controlled Release;2024-10

2. HER3 receptor and its role in the therapeutic management of metastatic breast cancer;Journal of Translational Medicine;2024-07-17

3. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs;Cancer Drug Resistance;2024-04-29

4. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned;Journal of Hematology & Oncology;2023-12-12

5. HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target;Cell Death Discovery;2023-10-28